Pulse Biosciences (PLSE) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-56.3M
Net Income
-53.6M
EPS (Diluted)
-$0.92
Balance Sheet Metrics
Total Assets
132.5M
Total Liabilities
17.6M
Shareholders Equity
114.9M
Debt to Equity
0.15
Cash Flow Metrics
Operating Cash Flow
-39.2M
Free Cash Flow
-36.5M
Revenue & Profitability Trend
Pulse Biosciences Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 700.0K | 1.4M | 0 |
| Cost of Goods Sold | - | 0 | 11.9M | 2.0M | 0 |
| Gross Profit | - | 0 | -11.2M | -550.0K | 0 |
| Operating Expenses | 56.3M | 43.6M | 46.8M | 62.5M | 50.0M |
| Operating Income | -56.3M | -43.6M | -58.1M | -63.0M | -50.0M |
| Pre-tax Income | -53.6M | -42.2M | -58.5M | -63.7M | -49.9M |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Net Income | -53.6M | -42.2M | -58.5M | -63.7M | -49.9M |
| EPS (Diluted) | -$0.92 | -$0.87 | -$1.69 | -$2.24 | -$2.10 |
Income Statement Trend
Pulse Biosciences Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 119.4M | 45.3M | 62.1M | 36.6M | 22.3M |
| Non-Current Assets | 13.0M | 13.8M | 15.7M | 17.6M | 19.0M |
| Total Assets | 132.5M | 59.2M | 77.9M | 54.2M | 41.3M |
| Liabilities | |||||
| Current Liabilities | 10.1M | 6.7M | 6.0M | 8.5M | 7.6M |
| Non-Current Liabilities | 7.5M | 8.1M | 74.1M | 10.0M | 10.8M |
| Total Liabilities | 17.6M | 14.8M | 80.1M | 18.6M | 18.4M |
| Equity | |||||
| Total Shareholders Equity | 114.9M | 44.4M | -2.2M | 35.7M | 22.9M |
Balance Sheet Composition
Pulse Biosciences Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -53.6M | -42.2M | -58.5M | -63.7M | -49.9M |
| Operating Cash Flow | -39.2M | -33.5M | -56.0M | -52.5M | -38.4M |
| Investing Activities | |||||
| Capital Expenditures | -125.0K | -121.0K | -401.0K | -437.0K | -441.0K |
| Investing Cash Flow | -125.0K | -121.0K | -401.0K | 7.6M | 10.0M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 59.4M | -6.0K | 143.6M | 55.3M | 29.4M |
| Free Cash Flow | -36.5M | -33.2M | -47.4M | -54.5M | -35.8M |
Cash Flow Trend
Pulse Biosciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-18.29
Forward P/E
-18.09
Price to Book
9.24
PEG Ratio
-18.09
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-77.86%
Return on Assets
-43.61%
Financial Health
Current Ratio
15.58
Debt to Equity
7.24
Beta
1.63
Per Share Data
EPS (TTM)
-$0.99
Book Value per Share
$1.76
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| plse | 1.1B | -18.29 | 9.24 | -77.86% | 0.00% | 7.24 |
| Intuitive Surgical | 189.7B | 77.39 | 11.09 | 15.96% | 28.41% | 0.00 |
| Becton, Dickinson | 50.0B | 33.87 | 1.98 | 5.89% | 7.18% | 76.34 |
| Lemaitre Vascular | 1.9B | 42.77 | 5.48 | 13.77% | 19.96% | 53.33 |
| AtriCure | 1.6B | - | 3.46 | -8.38% | -7.95% | 17.03 |
| Azenta | 1.5B | -10.80 | 0.90 | -8.58% | -9.77% | 3.16 |
Financial data is updated regularly. All figures are in the company's reporting currency.